# SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma

> **NCT02807181** · PHASE2,PHASE3 · TERMINATED · sponsor: **Sirtex Medical** · enrollment: 89 (actual)

## Conditions studied

- Intrahepatic Cholangiocarcinoma

## Interventions

- **DRUG:** Cisplatin-gemcitabine
- **DEVICE:** Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)

## Key facts

- **NCT ID:** NCT02807181
- **Lead sponsor:** Sirtex Medical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-14
- **Primary completion:** 2021-04-29
- **Final completion:** 2021-04-29
- **Target enrollment:** 89 (ACTUAL)
- **Why stopped:** Slow enrollment
- **Last updated:** 2025-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02807181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02807181, "SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02807181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*